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UPDATING THE PATENT SYSTEM’S
NOVELTY REQUIREMENT TO PROMOTE
SMALL-MOLECULE MEDICINAL
PROGRESS
JASON BREWER*
I.

INTRODUCTION

In 1928, the accidental contamination of a bacteria culture
dish with a spore from Penicillium Notatum spawned the greatest
life-saving drug that the world had ever seen, Penicillin.1 The
phenomenal discovery of the effect of small molecules, like
penicillin, on biological systems ignited the pharmaceutical
industry.2 Like other inventive industries, the pharmaceutical
industry protects its intellectual property investment under patent
law.3 Specifically, patent law affords protection only for novel,
* Jason Brewer received a BA in Chemistry from the University of Kentucky
and a MS in Chemistry from Northeastern University. He is a medicinal
chemist and has worked in the field for most of a decade. Jason is an author on
multiple scientific publications and an inventor on multiple patent
applications. In addition, he is currently a candidate for a JD from The John
Marshall Law School in May 2013. Jason would like to thank his wife,
Jennifer Brewer, for her love, hard work, and support, but most of all, for her
belief in him.
1. David Ho, Bacteriologist Alexander Fleming, TIME, Mar. 29, 1999, at
117,
available
at
http://www.time.com/time/magazine/article/0,9171,990612,00.html. Alexander
Fleming left a culture dish of Staphylococcus bacteria out while he was gone
over a two-week period. Id. Upon returning Fleming noted an area clear of
Staphylococcus surrounding a mold contaminate. Id. The name Penicillin was
derived from the name of the mold, Penicillium Notatum. Id.
2. Id. A wide range of penicillin derivatives now exist in the medicinal
market place. See Gordon L. Coppoc, Penicillin Derivatives, PURDUE
RESEARCH
FOUNDATION
(Mar.
27,
1996),
http://www.cyto.purdue.edu/cdroms/cyto2/17/chmrx/penems.htm
(providing
descriptions of various penicillin derivatives and their uses). Some examples
include: Penicillin G; Penicillin V; Ampicillin; Amoxicillin; Hetacillin;
Methicillin; Cloxacillin; dicloxacillin; Nafcillin; Oxacillin; Azlocillin;
Carbenicillin; Mezlocillin; Piperacillin; and Ticarcillin. Id.
3. See, e.g., U.S. Patent No. 5,559,111 (filed Apr. 4, 1995) (claiming
Tekturna in claim 19); U.S. Patent No. 7,109,205 (filed June 24, 2003)
(claiming Letaris as the racemate in claim 7); U.S. Patent No. 8,256,346 (filed
Nov. 3, 1994) (claiming Clevidipine in claim 3); U.S. Patent 5,223,510 (filed
July 26, 1991) (claiming Multaq in claim ten); U.S. Patent No. 7,160,870 (filed
May 24, 2001) (claiming Promacta in claim one); U.S. Patent No. 7,101,866
1151
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useful, and non-obvious inventions.4 However, the novelty
requirement may in fact stifle future drug discovery.
For example, researchers may have discovered a cure for
cancer that will never be marketed.5 The obvious question is “Why
not?” The answer consists of two parts: first, the enormous cost
and risk associated with clinical trials prevent companies from
pursuing such research without a stable benefit;6 and second, our
current patent system does not provide enough protection to allow
companies to benefit from research on a known chemical
compound.7
This Comment briefly explains current patent law, and
suggests changes that will provide incentive to pharmaceutical
companies to pursue known small molecules. Section II introduces
a brief background of patent law and its policies, along with the
history behind its development. Section III analyzes the patent
law and policies, focusing on its effect on small-molecule medicinal
research. Specifically, Section III highlights several reasons that
the patent system’s novelty requirement stifles medicinal
progress. Section IV proposes changes to the patent law that will
provide exclusivity for known compounds with new medicinal uses,
as well as alternative legislation that will grant similar exclusivity
outside patent law.

(filed Aug. 3, 2001) (claiming Veramyst in claim one); U.S. RE38,551 (filed
Jan. 28, 2002) (claiming Vimpat in claim eight).
4. 35 U.S.C. §§ 102-03 (2012).
5. This is intended as a purely hypothetical statement. But see The DCA
Patents,
WWW.THEDCASITE.COM
(Nov.
26,
2011),
http://www.thedcasite.com/the_dca_patents .html (failing to find investors for
a simple nonnovel compound, dichloroacetic acid, because a patent could cover
only the method of treating cancer not the composition of matter).
6. See Dennis Fernandez et al., The Interface of Patents with the
Regulatory Drug Approval Process and How Resulting Interplay Can Affect
Market Entry, in INTELLECTUAL PROPERTY MANAGEMENT IN HEALTH AND
AGRICULTURAL INNOVATION: A HANDBOOK OF BEST PRACTICES 965, 966 (A
Krattiger
et
al.,
eds.,
2007),
available
at
http://www.iphandbook.org/handbook/chPDFs/ch10/ipHandbookCh%2010%2009%20Fernandez-HuieHsu%20Patent%20and%20FDA%20Interface%20rev.pdf (stating that the
F.D.A. requisite clinical trials alone can cost up to $500 million); see also
Global Pharmaceutical R&D Productivity Declining According to Thomson
Reuters,
CMR
International,
PR
NEWSWIRE,
http://www.prnewswire.com/news-releases/global-pharmaceutical-rdproductivity-declining-according-to-thomson-reuters-cmr-international97281019.html (last viewed Sept. 24, 2012) (noting that only ten percent of
new drug clinical candidates are marketed).
7. See 35 U.S.C. § 102 (stating that patent protection only extends to
novel inventions).
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II. BACKGROUND OF THE PATENT SYSTEM
A. Constitutional Authority for Patent Laws
Patent law is rooted in the Constitution.8 The Framers of the
Constitution debated the advantages and disadvantages of patents
before granting Congress the power to grant monopolies for the
useful arts.9 In the end, the Constitution grants Congress the
power “[t]o promote the Progress of Science and useful Arts, by
securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries.”10
The new Congress quickly exercised this grant of power in the
Patent Act of 1790.11 In the Act, Congress first listed the
requirements a patent petitioner must satisfy to obtain a patent,12
including: (1) a specification that would enable one skilled in the
art to practice the invention; (2) the invention must have utility;
and (3) the invention must be novel.13 The requirements today are
similar, except the novelty requirement has further narrowed
patentable subject matter by excluding obvious improvements.14
The Supreme Court of the United States stated that the purpose of
these requirements is “to find a balance between promoting
innovation and allowing the public to use and perfect the invention
for the good of the economy.”15

8. U.S. CONST. art. I, § 8, cl. 8.
9. Jefferson initially proposed that the bill of rights should completely
restrict monopolies because “the benefit even of limited monopolies is too
doubtful to be opposed to that of their general suppression.” Letter from
Jefferson to Madison (Dec. 20, 1787), in 1 THE REPUBLIC OF LETTERS 511, 512
(James Morton Smith ed., 1995); Letter from Jefferson to Madison (July 31,
1788), in 1 THE REPUBLIC OF LETTERS at 545. However, in 1789 Jefferson
seemingly changed his mind: “Monopolies may be allowed to persons for their
own productions in literature and their own inventions in the arts for a term
[of] years but no longer. . . .” Letter from Jefferson to Madison (Aug. 28, 1789),
in 1 THE REPUBLIC OF LETTERS at 630. See Edward Walterscheid, Patents and
the Jeffersonian Mythology, 29 J. MARSHALL L. REV. 269, 274-75 (1996)
(reciting Jefferson’s participation in the development of the patent system).
10. U.S. CONST. art. I, § 8, cl. 8.
11. Patent Act of 1790, 1 Stat. 109 (1790).
12. Id. Inventions covered included “any useful art, manufacture, engine,
machine, or device, or any improvement therein not before known or used.” Id.
at 110.
13. Id. at 109. “The specification shall contain a written description of the
invention, and of the manner and process of making and using it . . . to enable
any person skilled in the art . . . to make and use the same . . . .” 35 U.S.C.
§ 112 (2012). An invention must be useful to obtain a patent. 35 U.S.C. § 101
(2012). An invention cannot be patented if it is known, published, or patented.
35 U.S.C. § 102(a).
14. 35 U.S.C. § 103(a) (2012).
15. Bilski v. Kappos, 130 S. Ct. 3218, 3252-53 (2010).
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B. The Patent Right Is a Negative Right
A patent grants the patentee the right to exclude others from
“making, using, offering to sell, or selling the invention in the
United States” for a maximum period of twenty years.16 Possessing
a patent does not grant the patentee the right to make, use, or
offer to sell the invention.17 Therefore, if an inventor’s invention is
an improvement on a patented item, she must obtain permission
to use, make, or sell her invention from the original invention’s
patent holder.18
C. Patentable Inventions: Everything Under the Sun Modified by
Man
Today, patentable subject matter is broader than the original
Patent Act of 1790. Originally, the Patent Act of 1790 afforded
protection to “any useful art, manufacture, engine, machine, or
device, or any improvement therein not before known or used.”19
Most notably, the Act did not include new methods of using old
inventions.20 However, Congress and the courts have since
changed the law, and now it allows patents on new methods of
using old inventions.21 Since the 1952 Patent Act, the courts have
interpreted patentable inventions to include “anything under the
sun that is made by man.”22 With the limitation of “made by man,”
16. 35 U.S.C. § 271(a) (2012). The unauthorized “mak[ing], us[ing],
offer[ing] to sell, or sell[ing] any patented invention, within the United States”
is said to infringe the patent. Id. The patent life for a utility patent will begin
at issue and will end twenty years after the initial filing date. 35 U.S.C.
§ 154(a)(2) (2012). Design patents last for fourteen years from the date of
grant. 35 U.S.C. § 173 (2012).
17. 35 U.S.C. § 271(a).
18. Id.
19. 1 Stat. 110.
20. Id. Thomas Jefferson disfavored new-use patents on old products.
ROBERT MERGES & JOHN DUFFY, PATENT LAW AND POLICY: CASES AND
MATERIALS 387 (LexisNexis, 4th ed. 2007). The Supreme Court of the United
States would not allow new-use patents. See Roberts v. Ryer, 91 U.S. 150, 157
(1875) (recognizing using an old machine for a new purpose is not a new
invention).
21. See Ansonia Brass & Co. v. Elec. Supply Co., 144 U.S. 11, 19 (1892)
(stating a new use of an old device or process may be patentable if the new use
is not analogous to the old use, and the new use required inventive skill to
produce). The Patent Act of 1952 codified new-use patentability as a new
process. Patent Act of 1952, 66 Stat. 792 (1952); see also 35 U.S.C. § 100(b)
(2012) (defining process as “process, art or method, and includes a new use of a
known process, machine, manufacture, composition of matter, or material”).
See Pfizer Inc. v. Teva Pharma. USA Inc., 803 F. Supp. 2d 409, 457 (E.D. Va
2011) (finding that Pfizer did not commit inequitable conduct and that the
Viagra patent for use of treating erectile dysfunction is valid and enforceable).
22. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (upholding a patent
for a genetically modified bacteria capable of breaking down various elements
of crude oil).
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only laws of nature, natural phenomena, and abstract ideas are
unpatentable.23
D. The Required Specification
The patent process is a quid pro quo exchange.24 A patentee
must disclose how to make and use his invention as consideration
for the limited monopoly.25 This disclosure is the specification.
Statutorily, the specification must satisfy four requirements.26 It
must: (1) enable one skilled in the art to make and use the
invention; (2) contain a written description of the invention; (3)
contain the inventor’s best mode of practicing the invention; and
(4) contain definite claims.27 A failure to satisfy any one of these
requirements will void the patent.28
23. Diamond v. Diehr, 450 U.S. 175, 185 (1981). Laws of nature, natural
phenomena and abstract ideas are the only categories of inventions that are
not patentable in the United States. Lab. Corp. of Am. Holdings v. Metabolite
Labs., Inc., 548 U.S. 124, 126 (2006). Therefore, Einstein could not patent
E=mc2 and Newton could not patent the law of gravity. Diamond, 447 U.S. at
309. Natural minerals cannot be patented. Id. Electromagnetism, steam, the
heat of the sun, electricity and the qualities of metals are not patentable. Funk
Bros. Seed. Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948); O’Reilly v.
Morse, 56 U.S. 62, 116 (1853). The patentability of these inventions is barred
because protection of these inventions would impede rather than promote
progress. Lab. Corp. of Am. Holdings, 548 U.S. at 126. However, practical
application of the forbidden subject matter may be patentable. Diehr, 450 U.S.
187-88. Compare id. (holding a process for curing rubber that uses a
mathematical equation is patentable), with Gottschalk v. Benson, 409 U.S. 63,
71-72 (1972) (voiding a claim for a formula because it “has no substantial
practical application”), and Bilski, 130 S. Ct. at 3231 (ruling that a business
method of hedging risk is an unpatentable abstract idea); see also Telephone
Cases, 8 S. Ct. 778, 782 (1888) (ruling the telegraph machine’s use of
electricity is patentable); see also O’Reilly, 56 U.S. at 86 (sustaining the
patentability of machinery that uses the qualities of electricity).
24. J.E.M. Ag. Supply Inc. v. Pioneer Hi-Bred Int’l, Inc., 534 U.S. 124, 142
(2001).
25. See Grant v. Raymond, 31 U.S. 218, 224 (1832) (stating that the
monopoly “is the reward stipulated for the advantage derived by the public for
the exertions of individuals”); Suzanne Scotchmer & Jerry Green, Novelty and
Disclosure in Patent Law, 21 RAND J. ECON. 131 (1990) (discussing patent
disclosures); Vincenzo Denicolo & Luigi Franzoni, The Contract Theory of
Patents, 23 INT’L REV. L & ECON. 365 (2003) (discussing how patent law
incentivizes disclosures); WILLIAM CALLYHAN ROBINSON, THE LAW OF
PATENTS FOR USEFUL INVENTIONS: VOL. 1 23 (Little, Brown, & Co., 1890).
26. 35 U.S.C. § 112.
27. Id. Paragraph two requires that the specification concludes with claims
“particularly pointing out and distinctly claiming the subject matter” of the
invention. 35 U.S.C. § 112(b). These claims must be definite in order to inform
the public of the features protected via the monopoly. Permutit Co. v. Graver
Corp., 284 U.S. 52, 60 (1931).
28. See Consol. Elec. Light Co. v. McKeesport Light Co., 159 U.S. 465, 476
(1895) (invalidating indefinite claims); In re Wands, 858 F.2d 731, 740 (Fed.
Cir. 1988) (holding the invention was enabled because it would not require
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E. The Novelty Requirement
When The Patent Act of 1752 was passed, monopolies were
very unpopular with the general public.29 The cause of this general
grievance related to previous monopolies granted by the English
Crown for “royal favor[s].”30 These monopolies often controlled
entrance into certain industries and removed commodities from
the open market.31 Most notably, the monopoly on tea helped
ignite the Revolutionary War.32 The British Statute of Monopolies
attempted to eliminate the abuse of monopolies by limiting the
grant of monopolies to only “new manufactures.”33
Likewise, the first Congress interpreted the constitutional
grant to “promote progress” through monopolies as limited to novel
inventions.34 Statutorily, an invention cannot be patented if “the
invention was known or used by others in this country, or patented
or described in a printed publication in this or a foreign country,
before the invention . . . by the applicant.”35 When an invention
fails the novelty test, it is said to be anticipated.36
Interestingly, the conception of the invention is patentable,
but the product of conception is not.37 Accordingly, merely
prophetic disclosure may anticipate.38
In order for a printed disclosure to anticipate a later

undue experimentation to reproduce it); Gentry Gallery Inc. v. Berkline Corp.,
134 F.3d 1473, 1480 (Fed. Cir. 1998) (invalidating a claim because it was not
supported by the written description); Chemcast Corp. v. Arco Indus., 913 F.2d
923, 930 (Fed. Cir. 1990) (invalidating a patent because the inventor’s best
mode was not described).
29. MERGES & DUFFY, supra note 20, at 5.
30. Id.
31. See MERGES & DUFFY, supra note 20, at 5 (requiring a patent to run an
ale house).
32. Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 7 (1966).
33. MERGES & DUFFY, supra note 20.
34. 1 Stat. 109.
35. 35 U.S.C. § 102(a). An inventor can anticipate himself if “the invention
was patented or described in a printed publication in this or a foreign country
or in public use or on sale in this country, more than one year prior to the date
of the application for patent in the United States.” 35 U.S.C. § 102(b). Even if
the invention falls outside of 102(a)-(b), the invention can be anticipated by an
unpublished U.S. patent application. 35 U.S.C. § 102(e).
36. MERGES & DUFFY, supra note 20, at 360.
37. See Telephone Cases, 8 S. Ct. at 782-83 (ruling that Bell’s telephone
patent is enforceable even though at the time of application the idea was not
reduced to practice); see also Pfaff v. Wells Elec., 525 U.S. 55, 62-63 (1998)
(ruling that the mere conception of a computer chip, including an enabling
description, anticipated the patent application); Alexander Milburn Co. v.
Davis-Bournonville Co., 270 U.S. 390, 401 (1926) (allowing a patent disclosure
of a nonreduced to practice invention, where the invention was not claimed in
the patent, to anticipate the latter patent).
38. See Pfaff, 525 U.S. at 62-63 (holding a description and drawings of an
instrument to be patentable before being reduced to practice).
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invention, the single disclosure must enable the invention,39 and
disclose each and every element of the invention.40 Yet, an element
may be inherent.41 An inherent element is “the natural result
flowing from” the disclosure.42 Initially, the inherent element had
to be recognized by a skilled artisan, but the recognition
requirement is now arguable.43 The policy behind the inherent
anticipation doctrine is to prevent removal of inventions from the
public.44
But, even with strict novelty requirements, the Supreme
Court of the United States carved out an exception, known as the
accidental anticipation doctrine. This doctrine provides that it
would be “absurd” for an accidental and unnoticed production of
an invention to anticipate because the accidental production gave
nothing to the world.45 Thus, in order to promote progress the
courts have applied the doctrine and upheld patents on non-novel
inventions.46
39. Seymour v. Osborne, 78 U.S. 516, 555 (1870); Struthers Scientific &
Int’l Corp. v. Rappl & Hoenig Co., Inc., 453 F.2d 250, 255 (2d Cir. 1972).
40. Hoover Grp. Inc. v. Custom Metalcraft, Inc., 66 F.3d 299, 302 (Fed. Cir.
1995); Structural Rubber Prod. Co. v. Park Rubber Co., 749 F.2d 707, 716
(Fed. Cir. 1984); Scripps Clinic & Research Found. v. Genentech, Inc., 927
F.2d 1565, 1576 (Fed. Cir. 1991).
41. See In re Robertson, 169 F.3d 743, 745 (Fed. Cir. 1999) (reversing the
trial court’s ruling that a diaper with two fastening mechanisms inherently
disclosed a diaper with three fastening mechanisms); see also Cont’l Can Co.
USA, Inc. v. Monsanto Co., 948 F.2d 1264, 1269 (Fed. Cir. 1991) (vacating
summary judgment because the issue of inherency required trial).
42. Eli Lilly & Co. v. Barr Labs. Inc., 251 F.3d 955, 970 (Fed. Cir. 2001).
The “natural result flowing from administration of fluoxetine hydrochloride is
inhibition of serotonin uptake.” Id.
43. Compare In re Robertson, 169 F.3d at 745 (requiring recognition of
inherency by one skilled in the art), with Schering Corp. v. Geneva Pharma.,
Inc., 339 F.3d 1373, 1380 (Fed. Cir. 2003) (dismissing the requirement of one
skilled in the art to recognize inherency to anticipate a metabolite).
44. See Schering Corp. 339 F.3d at 1380 (using the inherent anticipation
doctrine to prevent a patent for a metabolite of Loratidine that would prevent
commercializing a generic form of Loratidine); see also SmithKline Beecham
Corp. v. Apotex Corp., 365 F.3d 1306, 1313 (Fed. Cir. 2004) (denying
SmithKline’s attempt to patent a new isoform of paroxetine, a hydrochloride
hemihydrate, that is produced when making previously patented paroxetine
hydrochloride); but see SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d
1328, 1329 (Fed. Cir. 2005) (Newman, J., dissenting) (expressing concern over
the expansion of the inherent anticipation doctrine which may call into
question many previous patents, and ignores the accidental anticipation
doctrine).
45. Tilghman v. Proctor, 102 U.S. 707, 711-12 (1873); Edison Elec. Light
Co. v. Novelty Incandescent Lamp Co., 167 F. 977, 980 (3d Cir. 1909).
46. See Tilghman, 102 U.S. at 711-12 (ruling the accidental production of
glycerin and amino acids in a steam cylinder from the lubricant does not
anticipate an understood process for producing glycerin and amino acids); see
also Edison Elec. Light Co. v. Novelty Incandescent Lamp Co., 167 F. 977, 980
(3d Cir. 1909) (validating a patent for light bulbs where glass covers the
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F. Obviousness: A Further Expansion of the Novelty Requirement
Obviousness expands the novelty requirement by allowing the
combination of elements from multiple disclosures.47 While
reviewing the obviousness statute, the Supreme Court stated in
dicta, “Congress may not authorize the issuance of patents whose
effects are to remove existent knowledge from the public domain,
or to restrict free access to materials already available.”48 After
reviewing the statute, the Supreme Court upheld it, but developed
its own obviousness test.49
In general, the “combination of familiar elements according to
known methods is likely to be obvious when [the combination] does
no more than yield predictable results.”50 Yet, a different
obviousness analysis has developed for chemical compounds.51 For
platinum even though such light bulbs were made prior on accident, and
especially because the accidental light bulbs were actually thrown out); see
also Appl. of Seaborg, 328 F.2d 996, 998 (Fed. Cir. 1964) (validating a patent
although the isotope may have been produced in minute undetectable
quantities via a known process).
47. See Appl. of Winslow, 365 F.2d 1017, 1018-19 (Fed. Cir. 1966)
(combining multiple references to find the invention not patentable). An
inventor is presumed to know all prior art references. Id. An invention is
obvious “if the differences between the subject matter sought to be patented
and the prior art are such that the subject matter as a whole would have been
obvious at the time the invention was made to a person having ordinary skill
in the art to which said subject matter pertains.” 35 U.S.C. § 103(a).
48. John Deere, 383 U.S. at 6. The Court cited the constitutional
requirement of “progress” as necessitating the limitation. Id. The Supreme
Court of the United States’s first review of 35 U.S.C. § 103 obviousness
occurred in Graham v. John Deere. Id. at 3. The Court recognized precedent
for obviousness from Hotchkiss v. Greenwood. Id. at 10; See generally
Hotchkiss v. Greenwood, 52 U.S. 248 (1851) (invalidating a patent on
doorknobs where the only change from the prior art was the material from
which the doorknob was made). In the epic case of John Deere, the invention
in question was a simple plow that combined known mechanical elements to
absorb shock and prevent breakage. John Deere, 383 U.S. at 4. The Court
invalidated the patent because there were “no operative mechanical
distinctions, much less nonobvious differences.” Id. at 26.
49. Id. at 17. One must determine (1) the scope and content of the prior
art, (2) differences between the invention and the prior art, and (3) the level of
ordinary skill in the pertinent art. Id. Secondary considerations such as
“commercial success, long-felt but unresolved needs, and failure of others” are
addition factors. Id.
50. KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007). See id. at 422
(voiding a claim because combination of prior art, a sensor and an adjustable
pedal, would be obvious to one of skill in the art).
51. See In re Hass, 141 F.2d 122, 125 (Fed. Cir. 1944) (ruling that a
homolog could not be patented unless it possessed some “unobvious or
unexpected beneficial properties not possessed by a homologous compound
disclosed in the prior art”). To avoid obviousness, and promote progress, the
court directed its obvious analysis to all properties of a compound and not just
similarity of structure. Appl. of Papesch 315 F.2d 381, 385-86 (Fed. Cir. 1963);
see id. at 383 (ruling that the compound was patentable over a homolog
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chemical compounds, structural similarity only supports a prima
facie case of obviousness and shifts the burden of proof to the
applicant to show that the compound possesses unexpectedly
improved properties.52 Indeed, one generally cannot predict the
biological properties of a chemical compound based on similar
compounds.53 For example, an exchange of a deuterium for a
hydrogen may provide the distinction required for patentability.54
Therefore, the applicant may rebut obviousness simply by showing
that the compound possesses unexpected properties that a
structurally similar compound does not.55
G. Small-Molecule Medicinal Progress
The overarching policy of patent law is to promote progress.56
With this goal in mind, one should ask whether the patent system
has promoted medicinal progress. Progress in the medicinal field
can be measured by changes in life expectancy and improved
quality of life. In the United States, the life expectancy of an

because it possessed anti-inflammatory activity and the homolog did not).
Relying on the recent John Deere decision, the Court of Appeals for the
District of Columbia ruled that all “relevant facts” including a compound’s
beneficial properties, must be considered in an obvious analysis. Comm. of
Patents v. Deutsche Gold-und-Siber-Scheikansalt Vormals Roessler, 397 F.2d
656, 662 (D.C. Cir. 1968). Most interestingly, in Appl. of Stremniski,
Stremniski did not bear the burden of proving unexpected differences between
his compound and the prior art because the prior art showed no significant use
or property and Stremniski showed a use for his compound. Appl. of
Stremniski, 444 F.2d 581, 588 (Fed. Cir. 1971). The court reasoned its decision
would satisfy the constitutional requirement to promote progress. Id.
52. In re Grabiak, 769 F.2d. 729, 731 (Fed. Cir. 1985); See id. (finding no
prima facie case because prior art did not teach similarity between a thioester
and an ester group). See Appl. of Wilder, 563 F.2d 457, 459-60 (Fed. Cir 1977)
(finding prima facie case of obviousness for adjacent homologs and structural
isomers); see also Appl. of May, 574 F.2d 1082, 1089 (Fed. Cir. 1978) (finding a
prima facie case of obviousness for steroisomers); In re Hoch, 428 F.2d 1341,
1343 (Fed. Cir. 1970) (finding a prima facie case of obviousness for an acid
from an ethyl ester).
53. Kristen C. Buteau, Deuterated Drugs: Unexpectedly Nonobvious?, 10 J.
HIGH TECH. L. 22, 38 (2009).
54. Id. Unexpected properties may relate to a pharmacokinetic property,
such as a compound’s toxicity profile, bioavailability, or stability. Id. at 39. See
Liming Shao & Michael Hewitt, The Kinetic Isotope Effect in the Search for
Deuterated Drugs, 23 DRUG NEWS & PERSPECTIVES 398, 398 (2010) (showing
the exchange of a deuterium for a hydrogen may increase the metabolic
stability of a compound).
55. See Sanofi-Synthelabo v. Apotex Inc., 550 F.3d 1075, 1077, 1090 (Fed.
Cir. 2008) (finding the dextrotary enantiomer of clopidogrel, Plavix,
nonobvious due to unexpected potency and a preferable toxicity profile); see
also Appl. of May, 574 F.2d at 1084, 1093-94 (concluding that the lack of the
addictive effect of morphine analog enantiomers was unexpected and
nonobvious).
56. U.S. CONST. art. I, § 8, cl. 8.
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individual increased by more than twenty-seven years over the
last century.57 Examples of drugs that improve quality of life
include drugs that control pregnancy and treatments for
infections, pain, swelling, sinus allergies, nausea, and impotence.
Obviously, medicinal drug technology has flourished in the United
States positively affecting both life expectancy and lifestyle.
Again, “[t]he policy behind the patent system attempts to find
a balance between promoting innovation and allowing the public
to use and perfect the invention for the good of the economy.”58
Accordingly, the initial invention should trigger other inventions
and affect the economy. Promoting new small-molecule medicinal
drugs does both.
Once pioneering discovery efforts blossom, and new
medications are approved or new mechanisms of action are
discovered, cheaper therapies may be developed.59 For example, a
drug may be repurposed to treat multiple diseases.60 Alternatively,
follow-on drugs allow the pioneer drug to provide the proof of
concept or mechanism of action, and then improve on that drug or
provide a cheaper alternative.61 In regards to affecting the
economy, study results indicate that effective drug use may
decrease overall health costs.62 In effect, promoting drug discovery
affords other inventors with information, which allows them to
create better inventions, and therefore affects the economy
through lowering health care expenses.

57. Laura Shrestha, Life Expectancy in the United States, CRS REPORT FOR
CONGRESS, CRS-2 (Aug. 16, 2006), http://aging.senate.gov/crs/aging1.pdf.
58. Bilski, 130 S. Ct. at 3252-53.
59. Hongyu Zhao & Zongu Guo, Medicinal Chemistry Strategies in Followon Drug Discovery, 14 DRUG DISCOV. TODAY 516, 516 (2009); Daniel Grau, M.
Phil, & George Serbedzija, Innovative Strategies for Drug Repurposing, DRUG
DISCOVERY
&
DEVELOPMENT
(Sept.
6,
2007),
http://www.dddmag.com/innovative-strategies-for-drug.aspx.
60. Grau, Phil & Serbedzija, supra note 59. A repurposing approach is less
risky than a novel drug. Id. This is because it begins with a known safety
profile. Id. It may begin by screening known drugs against a wide range of
new targets. Id. For example, Finesteride was originally discovered to treat
prostate enlargement, but was repurposed to treat male hair loss. Id.
61. Zhao & Guo, supra note 59. During a follow-on discovery program,
scientists may analyze the information gathered from the pioneering drug to
develop new leads. Id. at 517. There are multiple examples of follow-on drugs.
Id. For example, although Atorvastatin, also known as Lipitor, was the fifth
statin to reach the market and it became the best-selling drug in history. Id.
However, follow-on programs still carry substantial risk. Id. at 521.
62. Yuting Zhang & Stephen B. Soumerai, Do Newer Prescription Drugs
Pay for Themselves? A Reassessment of the Evidence, 26 HEALTH AFFAIRS 880,
880 (2007). Although new drugs are expensive, their use may reduce the total
health care cost by replacing more expensive services. Id. However, more
studies need to be done. Id. at 885.
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III. THE NOVELTY REQUIREMENT STIFLES MEDICINAL PROGRESS
The United States Constitution grants Congress the power
“[t]o promote the Progress of Science and useful Arts, by securing
for limited Times to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries.”63 To this purpose, the
patent laws must “find a balance between promoting innovation
and allowing the public to use and perfect the invention for the
good of the economy.”64 It is historically true that the patent
system has successfully promoted medicinal technological
innovation to progress society as seen through the increase in life
expectancy and the improvement in lifestyle.65 This analysis will
show that: (A) society needs further medicinal progress; (B)
claiming compounds by structure is wasteful; and (C) novelty via
structure will stifle medicinal progress.
A. Progress Is Still Needed: The Risk-Benefit Imbalance
There are many diseases and illnesses still plaguing the world
for which there are no medicinal treatments.66 In fact one could
say “the ‘big cures’ have not been discovered [because]
[n]eurological damage, . . . chronic heart failure, chronic
obstructive pulmonary disease, many cancers, obesity and other
chronic conditions have few or no treatment options.”67
Furthermore, treatments for other diseases possess serious
adverse side effects.68 For example, 74% of persons who start
taking antipsychotics for schizophrenia and bipolar mania quit
taking the medication due to side effects.69 Hence, there is much
need for new treatments.
One major factor implicated in drug companies’ failure to
develop needed treatments is the imbalance of risk and benefit.70
63. U.S. CONST. art. I, § 8, cl. 8.
64. Bilski, 130 S. Ct. at 3252-53.
65. Shrestha, supra note 57.
66. Esther Schmid & Dennis Smith, Pharmaceutical R&D in the Spotlight:
Why Is There Still Unmet Medical Need?, 12 DRUG DISC. TODAY 998, 998
(2007).
67. Id. at 998-99.
68. See Eric M. Snyder & Melanie Murphy, Schizophrenia Therapy:
Beyond Atypical Antipsychotics, 7 NATURE REVIEWS DRUG DISC. 471, 471
(2008) (pointing out Zyprexa’s sideffects).
69. Id. Schizophrenia affects 1% of the population and bipolar disorder
affects 3% of the population. Id. Yet Zyprexa, “the most effective atypical
antipsychotic on the market,” lost half its market share due to side effects. Id.
70. New drugs take about twelve to fifteen years and $800 million to
develop and get to market. Frequently Asked Questions About Pharmaceutical
Research, GLAXOSMITHKLINE, http://us.gsk.com/html/healthcare/health carecommon-questions.html (last updated June 18, 2007). However, this drug was
only one of a million compounds screened. Id. In 1995, only one in five drugs
entering clinical trials entered the market. Prescription Drug Costs,
KAISEREDU.ORG
(Feb.
2010),
http://www.kaiseredu.org/Issue-
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Legislation in the area of medicinal drugs affects both risk and
benefit through F.D.A. regulation, patent grants and term, and
promoting litigation.71 With the high unmet medical need for
effective treatments, it is imperative that while the government

Modules/Prescription-Drug-Costs/Background-Brief.aspx; Di Masi & Joseph
A., Success Rates for New Drugs Entering Clinical Testing in the United
States, 58 CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1 (1995). However
by 2006 the success rate had dropped to one in ten. Zhao & Guo, supra note
59, at 516. Exemplifying the risk, between 1995 and 1999 fifty neuroprotective
drugs were tested at a cost of “almost $6 billion in clinical trial costs alone,
without even counting the discovery and preclinical costs” and all failed to
show efficacy. Schmid & Smith, supra note 66, at 998-99.
71. F.D.A. regulation has led to a “dramatic increase in costs” in the search
for new drugs. Richard Cheung et al., Orphan Drug Policies: Implications for
the United States, Canada, and Developing Countries, 12 HEALTH L. J. 183,
184 (2004). Drugs are regulated by the F.D.A. for both safety and efficacy.
Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a)-(b) (2012). Congress passed
The Food, Drug, and Cosmetic Act of 1938 after 107 people died from a
marketed toxic elixir. Legislation, U.S. FOOD AND DRUG ADMINISTRATION (Jul.
9, 2012), www.fda.gov/regulatoryinformation/legislation/ default.htm. The
Defauver-Harris Amendment of 1962, which requires drugs to be proven both
safe and effective, was passed after the marketing of Thalidomide, a treatment
for morning sickness, which caused the improper growth of fetuses. Cheung et
al., supra, at 183-84; Promoting Safe and Effective Drugs for 100 Years, U.S.
FOOD
AND
DRUG
ADMINISTRATION
(June
18,
2009),
http://www.fda.gov/AboutFDA/WhatWeDo/
History/CentennialofFDA/CentennialEditionofFDAConsumer/ucm093787.htm.
The F.D.A. approval process costs between $100 and $500 million. Dennis
Fernandez et al., supra note 6. Thus drug development is obstructed by legal
requirements “for the very proper, laudable and desirable aim of making drugs
as safe as possible.” Miles Weatherall, Limitations on the Discovery and
Supply of Medicines, 67 PROC. ROYAL SOC. MED. 1287, 1288 (1974),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1645783/pdf/procrsmed003130020.pdf. There is no such thing as a perfectly safe drug, merely a statistical
balance of risk. Id. at 1289. Instead the “[p]ublic demand for totally safe drugs
has led to excessive, costly and misleading toxicity testing.” Miles Weatherall,
An End to the Search for New Drugs, 296 NATURE 387, 387 (1982). This
demand reduces the resources available to discover new drugs. Id. Further
complicating the issue, the F.D.A. is more likely to deny market entry than
allow entry in order to protect itself. Limitations on the Discovery and Supply
of Medicines, supra, at 1289. The F.D.A. will get blamed if the drug has
negative side effect, but if there is no drug then the public blames
pharmaceutical companies. Id. Therefore, “we are wasting a large amount of
labour and resources on collecting evidence which can only damn the drug and
which will not add to its potential therapeutic use.” Id.
The exclusivity period is expressly spelled out in the patent law. 35 U.S.C.
§ 154(a)(2). Historically the government extended the patent term for patent
office and F.D.A. delays. 35 U.S.C. §§ 154(b)(1), 155. However, the patent will
not be extended beyond fourteen years. Fernandez et al., supra note 6.
The Hatch-Waxman Act actually promotes litigation by granting an
exclusivity period to the first generic company to submit the first abbreviated
new drug application (ANDA). Ashlee Mehl, Comment, The Hatch-Waxman
Act and Market Exclusivity for Generic Drug Manufacturers: an Entitlement or
an Incentive?, 81 CHI.-KENT L. REV. 649, 650 (2006).
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strives to balance other social policies, it must also strive to uphold
the constitutional mandate to promote medicinal progress.
B. Claiming Compounds by Structure Is a Loss to Society
Novelty is the quintessential requirement to obtain a
patent.72 This requirement stems from an antiquated fear of
misuse inherited from the English crown.73 Consequently, the
patent laws forbid composition-of-matter protection if “the
invention was known or used . . . or patented or described in a
printed publication . . . before the invention . . . by the applicant.”74
Yet, when relating to chemical compositions, requiring novelty
purely by chemical structure removes all incentive to develop
known chemical entities and causes society to lose out on many
small-molecule drugs.75
1. Method Claims Are NOT the Answer
The 1952 Patent Act provided that a new method of use for an
old invention could be patented, a “use patent.”76 However, the
scope of protection granted to a new use is less than that offered to
a new composition of matter.77 The risk associated with weaklyprotected method of use patents is well recognized.78
Due to this inherent risk companies may avoid investment in
compounds protected only via method of use patents.79 Weakness
in method of use patents stems from case law and policy,
enforcement problems, and easy work-arounds for would-be

72. 35 U.S.C. § 102.
73. See John Deere, 383 U.S. at 7 (stating the monopoly on tea “sparked”
the Revolutionary War).
74. 35 U.S.C. § 102(a). An inventor can anticipate himself if “the invention
was patented or described in a printed publication . . . or in public use or on
sale . . . more than one year prior to the date of the application for patent.” 35
U.S.C. § 102(b). Even if the invention falls outside of § 102(a)-(b), the invention
can be anticipated by an unpublished U.S. patent application. 35 U.S.C.
102(e).
75. Supra § III(B)(4)(c) and corresponding endnotes; see The DCA Patents,
supra note 5 (discussing the difficulty to market a known compound).
76. See 35 U.S.C. § 100(b) (defining process as “process, art or method, and
includes a new use of a known process, machine, manufacture, composition of
matter, or material”).
77. Harold L. Marquis, An Economic Analysis of the Patentability of
Chemical Compounds, 63 J. PAT. OFF. SOC’Y 3, 4 (1981).
78. See Phil Milford, Pfizer Viagra Patent Ruled Valid by Judge in Loss for
Teva,
BLOOMBERG
BUSINESSWEEK
(Aug.
15,
2011),
http://www.businessweek.com/news/2011-08-15/pfizer-viagra-patent-ruledvalid-by-judge-in-loss-for-teva.html (voicing amazement that Pfizer’s Viagra
patent for treating impotence was held valid because method of use patents for
small molecules usually “don’t hold up that well in court”).
79. See The DCA Patents, supra note 5 (discussing the difficulty to market
a known compound).

Do Not Delete

1164

10/27/2012 3:08 PM

The John Marshall Law Review

[45:1151

infringers. The court cases indicate either that the court disfavors
method of use claims or that the claims are incredibly difficult to
write.80 Further, infringement is difficult to track because the
“mere sale is not per se infringement.”81 Finally, because the base
compound is not protected via a composition-of-matter patent, an
infringer may avoid the patent by making different polymorphs.82
At bottom, because of the weak protection afforded a method of use
patent, its benefit cannot balance the risk and cost of medicinal
discovery.
2. Prior Art by Structure Leads to Inefficient Use of Chemical
Space
A single published disclosure of an invention will prevent the
inventor from obtaining a patent: the invention is anticipated.83
For chemical entities, disclosure of a molecular structure will
anticipate that structure.84 But, disclosure of chemical entities
occurs for many reasons other than their utility. For example,
many compound structures are published for purely academic
reasons, such as developing synthetic methodology, educational
projects, synthetic dissertations, and unrepeatable disclosures
caused by professors’ desperation to obtain tenure.85
80. See Sun Pharma. Indus. Ltd. v. Eli Lilly & Co., 611 F.3d 1381, 1389
(Fed. Cir. 2010) (invalidating a patent for a method of treating cancer with
Gemzar).
81. MERGES & DUFFY, supra note 20, at 390. Tracking down users that
infringe is incredibly expensive. Id. Additionally, other laws allow doctors to
prescribe any “FDA approved drug for off label use.” Id.
82. See Sasha Coffiner, Cephalon Settlemen with Generic Makers in
Nuvigil Patent Suits Could Be Delayed by Ongoing Anti-Trust Litigation –
Experts,
PHARMAWIRE
(May
19,
2010)
http://www.wolfgreenfield.com/files/cephalon_article_pdf.pdf (pointing out that
generic manufacturers may work around the patent by making a different
polymorph because there is not a composition-of-matter claim).
83. See 35 U.S.C. § 102(a) (stating inventions that are patented or
published by another cannot be patented); see also 35 U.S.C. § 102(b) (stating
an inventors own publication may anticipate); 35 U.S.C. § 102(e) (stating
unpublished U.S. patent applications will anticipate later inventions).
84. See Sun Pharma. Indus. Ltd., 611 F.3d at 1389 (ruling that the claim
was anticipated by an earlier disclosure of the compound structure).
85. See generally Jason Brewer et al., A Systematic Study of the
Relationship Between Molecular and Crystal Structure Among 3,5Diazabicyclo[2.2.2]octane-2,6-diones, 4 CRYSTAL GROWTH AND DESIGN, 591
(2004),
http://www.chem.uky.edu/xray/people
_documents/parkin/Parkin_Papers_pdfs/93_CGDv4n3p591.pdf (showing my
undergraduate synthetic work, where the major purpose was to obtain
synthetic experience); see generally Ronald Have et al., Novel Synthesis of 4(5)Monosubstituted Imidazoles via Cycloaddition of Tosylmethyl Isocyanide to
Aldimines, 53 TETRAHEDRON 11355 (1997) (teaching a method to synthesized
imidazoles, not a use for the compounds synthesized); see also Asher Mullard,
Reliability of ‘New Drug Target’ Claims Called into Question, 10 NATURE R.
DRUG DISCOVERY 643, 643 (2011); and John P. A. Ioannidis, Why Most
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Another major form of disclosure includes patents and patent
applications.86 Markush claims allow inventors to make claims in
the alternative.87 For example, one part of the compound may be
“selected from the group consisting of A, B and C.”88 Notably,
chemical composition-of-matter patents claim millions or billions
of compounds through the use of Markush claims.89
Simply, Markush claims are wasteful. Because the claim
protects the invention, which is the concept, often the inventor
never synthesizes or reduces to practice the majority of the
claimed compounds.90 Thus, the product itself is never really given
to society. But, by utilizing Markush claims the inventor increases
the protection surrounding his invention.91 Thus, this incentive
causes inventors to claim too broadly.92 Although one may argue
that a Markush claim may not completely prevent a patent on a
specific species,93 the fact remains that companies will avoid the
Published Research Findings are False, 2 PLOS MEDICINE 696, 696 (2005),
available
at
http://www.plosmedicine.org/article/info:doi/
10.1371/journal.pmed.0020124 (pointing out that the majority of published
research data is false).
86. See 35 U.S.C. § 102(a), (e) (stating printed publications and
unpublished patent applications will anticipate later inventions).
87. Id.; see generally Ex Parte Markush, 1925 C.D. 126 (Comm’r Pat. 1925)
(discussing alternative claims).
88. Markush Claims, 803.02 MANUAL OF PATENT EXAMINING PROCEDURE
R5, available at http://www.zpatents.com/mpep/documents/0800_803_02.htm.
89. Steve Gardner & Andy Vinter, Beyond Markush – Protecting Activity
not
Chemical
Strucuture,
1
http://www.cressetgroup.com/publications/Beyond_Markush .pdf (last visited Sept. 25, 2012).
90. See Telephone Cases, 8 S. Ct. at 782-783; Pfaff, 525 U.S. at 60;
Alexander Milburn Co., 270 U.S. at 402 (1926) (each showing that the
invention is the concept and reduction to practice is not necessary for a
patent); see generally PCT Patent App. No. 2010/124042 (filed Apr. 23, 2009);
U.S. Patent No. 5,559,111 (filed Apr. 4, 1995); U.S. Patent No. 7,109,205 (filed
June 24, 2003); U.S. Patent No. 8,256,346 (filed Nov. 3, 1994); U.S. Patent
5,223,510 (filed July 26, 1991); U.S. Patent No. 7,160,870 (filed May 24, 2001);
U.S. Patent No. 7,101,866 (filed Aug. 3, 2001); U.S. RE38,551 (filed Jan. 28,
2002); PCT Patent App. No. 2010/124042 (filed Apr. 23, 2009) (each showing
most of the Markush claimed compounds do not appear in the examples).
91. See 35 U.S.C. § 102 (stating an invention is not patentable if it is not
novel; see also 35 U.S.C. § 103 (stating an invention is not patentable if it is an
obvious variation of another invention).
92. See generally PCT Patent App. No. 2010/124042 (filed Apr. 23, 2009);
U.S. Patent No. 5,559,111 (filed Apr. 4, 1995); U.S. Patent No. 7,109,205 (filed
June 24, 2003); U.S. Patent No. 8,256,346 (filed Nov. 3, 1994); U.S. Patent
5,223,510 (filed July 26, 1991); U.S. Patent No. 7,160,870 (filed May 24, 2001);
U.S. Patent No. 7,101,866 (filed Aug. 3, 2001); U.S. RE38,551 (filed Jan. 28,
2002); PCT Patent App. No. 2010/124042 (filed Apr. 23, 2009) (each showing
the breadth of Markush claiming beyond the reduced to practiced molecules).
93. See Appl. of Petering, 301 F.2d 676 (Fed. Cir. 1962) (creating the
genus-species test by ruling that only the members of a genus that the
inventor could “at once envisage” would be precluded from further patenting).
This test remains in use today. See Sanofi-Synthelabo, 550 F.3d at 1084; Eli
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risk associated with Markush anticipation, and avoid Markush
claimed compounds.
As shown, many non-useful disclosures of chemical structures
exist. These disclosures may comprise unrepeatable academic
expenditures or broadened protection through Markush
claiming.94 Unfortunately, these nonuseful structural disclosures
remove the molecules cited from composition-of-matter patentable
space and remove the incentive for pharmaceutical companies to
develop them.95
3. Medicinal Chemical Space Is Finite
Different chemical structures possess different chemical
properties. Some structures have been identified as possessing
favored properties in medicinal drugs.96 These compounds have
been labeled “privileged structures.”97 Because of previous work,
there now exists very little patentable space around these
biologically favored compounds.98
Other compounds have been shown to be limited by their
physicochemical properties.99 Some of these properties include the
number of hydrogen bond donors or acceptors, molecular weight,
lipophilicity, and polar surface area.100 According to Lipinski’s
Lilly & Co. v. Zenith Goldline Pharms., Inc., 471 F.3d 1369, 1376 (Fed. Cir.
2006) (citing Appl. of Petering).
94. Ioannidis, supra note 85; Mullard, supra note 85; Markush Claims,
supra note 88; U.S. Patent No. 7,160,870 (filed May 24, 2001); U.S. Patent No.
7,101,866 (filed Aug. 3, 2001).
95. 35 U.S.C. § 102(a)-(b), (e).
96. R.W. DeSimone et al., Privileged Structures: Applications in Drug
Discovery, 7 COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
473, 473 (2004).
97. Id. “[P]rivileged structures are molecular scaffolds with versatile
binding properties, such that a single scaffold is able to provide potent and
selective ligands for a range of different biological targets through
modification of functional groups.” Id. Privileged structures “generally contain
two or three ring systems connected by single bonds or by ring fusion.” Id. at
474. For example, purines have been used in anticancer, antibiotic, antifungal
and antiviral therapeutics. Id. at 477. 1,4-Dihydropyridines have also
exhibited activity across a variety of receptors. Id. at 478. Additionally, indoles
are “richly represented in marketed drugs.” Id. at 479. A few other examples
include spiropiperidines, benzimidazoles, benzofurans, and benzopyrans. Id. at
482-487.
98. See generally DeSimone et al., supra note 96 (citing a few examples of
privileged structures in multiple drug compounds).
99. See M.A Navia & P.R. Chaturvedi, Design Principles for Orally
Bioavailable Drugs, 1 DRUG. DISC. TODAY 179, 181 (1996) (discussing
availability of compound designs); W.M Pardridge, Transport of Small
Molecules Through the Blood-brain Barrier: Biology and Methodology, 15
ADVANCED DRUG DELIVERY REV. 5, 12 (1995) (indicating that high molecular
weight limits intestinal and blood brain barrier permeability).
100. Christopher A. Lipinski et al., Experimental and Computational
Approaches to Estimate Solubility and Permeability in Drug Discovery and
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“rule of 5,” “poor absorption or permeability are more likely when”
a compound’s molecular weight is “over 500,” the “LogP is over 5,”
and there are more than ten hydrogen bond donors.101 A
combination of two of these factors showed a less than 10% chance
for the compound to enter clinical trials.102 Additionally, in a
recent Pfizer paper, cLogP and polar surface area were correlated
with toxicity.103 In short, the correlation between physicochemical
properties and successful drugs limits medicinal chemical space.104
4. Historic and Current Policies Support Expanding the Novelty
Requirement for Medicinal Drugs
The Constitution granted Congress the power “[to] promote
the Progress of Science and useful Arts” through the patent
system.105 Congress then created the novelty requirement as
protection from abuses of monopolies similar to those of the
English Crown.106 However, there have been exceptions to the
novelty rule.
a. The Doctrine of Accidental Anticipation Supports Patenting
Useful Productions of Prior Art
The Supreme Court of the United States created the doctrine
of accidental anticipation. The doctrine provides an exception to
the novelty requirement. The doctrine provides that it would be
“absurd” for an accidental and unnoticed production of an
invention to prevent patentability because the accidental
production gave nothing to the world.107 Case law provides several
examples of the doctrine in chemical cases.
Examples include Tilghman v. Proctor108 and Application of
Seaborg.109 In Tilghman, the Supreme Court held that the
accidental production of glycerin and amino acids from the
lubricant in a steam cylinder did not anticipate an understood
process for producing glycerin and amino acids.110 Similarly, in
Seaborg, the Court validated a patent even though the isotope may
have been produced in minute, undetectable quantities via a
Development Settings, 46 ADVANCED DRUG DELIVERY REV. 3, 6-7 (2001); Jason
Hughes et al., Physicochemical Drug Properties Associated with In Vivo
Toxicological Outcomes, 18 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
4872, 4872 (2008).
101. Lipinski et al., supra note 100, at 9.
102. Id.
103. Hughes et al., supra note 100, at 4875.
104. Id.
105. U.S. CONST. art. I, § 8, cl. 8.
106. John Deere, 383 U.S. at 7.
107. Tilghman, 102 U.S. at 711-12.
108. Id. at 707.
109. Appl. of Seaborg, 328 F.2d 996.
110. Id.
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known process.111 So a mere unusable previous production in the
chemical arts does not necessarily anticipate a latter useful
production.
b. In an Obvious Analysis, Chemical Properties Are the
Patentable Invention
The nonobvious requirement expands the novelty
requirement, allowing the combination of elements from multiple
disclosures.112 However, when patenting chemical compounds,
structural similarity supports only a prima facie case of
obviousness, and shifts the burden of proof to the applicant to
show that the compound possesses unexpected, nonobvious,
improved properties.113 If a compound does possess an unexpected
property, then the compound is patentable.114 Interestingly, in
Application of Stemniski,115 Stemniski did not even bear the
burden of proving unexpected differences because the prior art did
not show a significant use or property.116 The Stemniski court
reasoned that allowing the patent would promote progress.117
Thus, courts have recognized that the properties and uses of
chemical compounds are the actual patentable invention, not the
molecular structure.
C. The Novelty Requirement Will Stifle Medicinal Progress
The patent system should promote innovation to cure the
unmet medical need. But instead, the current system will stifle
future drug discovery. Method of use patents do not offer strong
enough protection to support the huge financial burden associated
111. Appl. of Seaborg, 328 F.2d at 998.
112. See 35 U.S.C. § 103(a) (stating that an invention is obvious “if the
differences between the subject matter sought to be patented and the prior art
are such that the subject matter as a whole would have been obvious at the
time the invention was made to a person having ordinary skill in the art to
which said subject matter pertains”); see also Appl. of Winslow, 365 F.2d at
1018-20 (combining multiple references to find the invention not patentable).
113. See In re Grabiak, 769 F.2d. at 731 (finding no prima facie case because
prior art did not teach similarity between a thioester and an ester group); see
also Appl. of Wilder, 563 F.2d at 459-60 (finding prima facie case of
obviousness for adjacent homologs and structural isomers); see also Appl. of
May, 574 F.2d at 1089 (finding a prima facie case of obviousness for
steroisomers); see also In re Hoch, 428 F.2d at 1342 (finding a prima facie case
for an acid and an ethyl ester).
114. See Sanofi-Synthelabo, 550 F.3d at 1077, 1090 (finding the dextrotary
enantiomer of clopidogrel, Plavix, nonobvious due to unexpected potency and a
preferable toxicity profile); see also Appl. ofMay, 574 F.2d at 1084, 1093-94
(concluding that the lack of the addictive effect of a morphine analog
enantiomer was unexpected and nonobvious).
115. Appl. of Stemniski, 444 F.2d 581 (Fed. Cir. 1971).
116. Id. at 588.
117. Id.
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with drug discovery.118 The novelty requirement precludes many
compounds of interest due to the expansive prior art, including
prophetic Markush claims.119 Physicochemical properties and
privileged structures further limit the medicinal chemical space.120
Thus, current patent novelty requirements do not promote
progress of small-molecule medications due to extremely
inefficient use of the finite medicinal chemical space.
Some courts have recognized this fatal flaw in the patent
system. The Supreme Court’s accidental anticipation doctrine
recognizes the absurdity of placing unrecognized inventions within
the prior art.121 Obviousness cases have recognized that the
properties of a compound are the patentable feature.122 Thus, the
combination of the absurdity of removing compounds with
unrecognized properties from the patentable pool with the fact that
chemical properties are the patentable invention indicates a
supreme failure of current patent law to promote small-molecule
medicinal progress.
IV. ALTERNATIVES TO NOVELTY EXCLUSION VIA STRUCTURE
Drug companies are crumbling under the current patent
regime.123 The patent novelty requirement bears a portion of the
blame.124 The first Congress included the novelty requirement in
the Patent Act because it feared removal of inventions from the

118. Supra § III(B)(1) (explaining why method claims are not the answer).
119. Supra § III(B)(2) (showing that prior art by structure leads to
inefficient use of chemical space).
120. Supra § III(B)(3) (pointing out that medicinal chemical space is finite).
121. Tilghman, 102 U.S. at 711-12.
122. Supra § III(B)(4)(b) (pointing out that obviousness recognizes chemical
properties as the patentable invention).
123. See Jim Edwards, Yes, There Will be More Layoffs at Pfizer, as These
Numbers Show, CBS MONEY WATCH (June 8, 2011, 12:12 PM),
http://www.cbsnews.com/8301-505123_162-42848659/yes-there-will-be-morelayoffs-at-pfizer-as-these-numbers-show/?tag=bnetdomain (predicting goliath
pharmaceutical company Pfizer’s action to become more efficient and pointing
out that Pfizer laid off nearly 20,000 people in 2009 after acquiring Wyeth,
another pharmaceutical company); see also Frank Jordans, Novartis
Pharmaceutical Giant Plans 2,000 Layoffs Despite Profit Increase,
HUFFINGTON
POST
BUS.
(Oct.
25,
2011,
7:53
AM),
http://www.huffingtonpost.com/2011/10/25/novartis-layoffsprofit_n_1030137.html (telling of Novartis’ plan to cut jobs in the wake of price
pressures); see also Tracy Staton, Layoffs Return with Abbott’s 3,000 Job Cuts,
FIERCEPHARMA (Sept. 22, 2010), http://www.fiercepharma.com/story/layoffsreturn-abbotts-3-000-job-cuts/2010-09-22 (reporting that Abbot Laboratories
will cut three thousand jobs after acquiring Solvay). Maureen Martino, Roche
Plots Layoffs as it Focuses on R&D, FIERCEBIOTECH (Sept. 3, 2010),
http://www.fiercebiotech.com/story/roche-plots-layoffs-it-focuses-r-d/2010-09-03
(indicating that Roche plans to cut jobs).
124. 35 U.S.C. § 102.
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public.125 Unfortunately, Congress failed to see the stifling effect of
the novelty requirement on medical progress. This failure occurred
primarily because today’s technology driven medicinal chemical
arts were not practiced or understood when Congress passed the
initial Patent Act.126 Yet, Congress still has not recognized the
novelty problem associate with drug discovery. Simply put, smallmolecule medicinal research is: (1) extremely costly;127 (2) limited
via chemical properties to a finite number of compounds;128 and (3)
prevented from efficiently utilizing the finite number of
compounds with drug-like chemical properties because the novelty
requirement prevents composition-of-matter protection that could
balance the risk of development.129 This wasteful practice must
stop. Patent law should be reformed to promote the development of
known small-molecule drugs.
There are at least three options that will provide incentive to
develop known small molecules into medicines. These options
include: (A) amending the current patent laws; (B) providing a
simple common law fix; and/or (C) providing incentive for the
development of new drugs outside of the current patent law.
A. Amending the Patent Laws to Promote Progress
The Constitution affords Congress the power to grant
monopolies to promote progress, and thus the power to amend the
current patent law to promote progress.130 Specifically, two laws
may be amended to provide composition-of-matter protection for
known chemical entities with new medicinal uses. These laws
include (1) 35 U.S.C. § 101 and (2) 35 U.S.C. § 102. These statutes
should be amended to provide incentive to research compounds
that are known in the literature, but are not in use.

125. 1 Stat. 109; MERGES & DUFFY, supra note 20; see John Deere, 383 U.S.
at 7 (noting that tea was removed from the colonial public). However, the 1952
Act attempted to remedy the situation by allowing patents for new uses. See
35 U.S.C. § 100(b) (including a “new use for a known process” in the definition
of process). Unfortunately, the attempt failed to act as an incentive because of
the weak protection afforded method of use patents. Milford, supra note 78.
126. Compare 1 Stat. 109 (dating back to 1790) with Ho, supra note 1
(indicating penicillin was not discovered until 1928).
127. See Fernandez et al., supra note 6; (stating that the F.D.A. requisite
clinical trials alone can cost up to $500 million); see also Global
Pharmaceutical R&D Productivity Declining According to Thomson Reuters,
CMR International, supra note 6 (stating that only ten percent of new drug
clinical candidates are marketed).
128. Lipinski et al., supra note 100, at 9; Hughes et al., supra note 100, at
4875; DeSimone et al., supra note 96; supra § II(B)(3).
129. Supra § II(B)(2).
130. U.S. CONST. art. I, § 8, cl. 8; See generally Leahy-Smith America
Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) (showing Congress’s
willingness to pass new patent legislation).
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1. Amending 35 U.S.C. § 101131
Similar to the 1952 attempt to broaden the patentable
inventions, Congress may expand patent protection by amending
35 U.S.C. § 101.132 To promote patent protection for known small
molecules with an F.D.A. approved use, the following should be
added to the statute:133
Additionally, a known, non-commercialized chemical compound,
with a new F.D.A. approved use, that is not in public use, may
obtain composition-of-matter protection.

The amendment would protect against the abuse of removing
more than necessary from the public. In requiring F.D.A. approval
for the provision to apply, the amendment will limit the expansion
to medicinal chemical compounds, preventing chemical entities
without F.D.A. approval and with less expensive development
costs from public removal.134 Additionally, the limitation of “noncommercialized” and “not in public use” will prevent the removal
of compounds that are currently sold or in use.135

131. See 35 U.S.C. § 100(b) (amending the definition of process to include a
“new use for a known process”).
132. Id.
133. Thus the entire statute will read: “Whoever invents or discovers any
new and useful process, machine, manufacture, or composition of matter, or
any new and useful improvement thereof, may obtain a patent therefore,
subject to the conditions and requirements of this title.” Additionally, a
known, noncommercialized chemical compound with a new F.D.A. approved
use, that is not in public use, may obtain composition-of-matter protection. 35
U.S.C. § 101 (suggested amendment emphasized).
134. See Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a)-(b) (2011)
(ordering that drugs must be shown to be both safe and effective before
entering the market); F.D.A. regulation led to a “dramatic increase in costs” in
the search for new drugs. Cheung et al., supra note 71. Now new drugs take
about 12 to 15 years and $800 million to get to market. Frequently Asked
Questions About Pharmaceutical Research, supra note 70. Thus, allowing a
patent on a known unused compound will not be like removing tea, a plant,
from the market. See John Deere, 383 U.S. at 7 (stating that the monopoly on
tea sparked the Revolutionary War).
135. See Bilski, 130 S. Ct. at 3252-53 (quoting Bonito Boats Inc. v. Thunder
Craft Boats, Inc., 489 U.S. 141, (1989), stating patent laws must find a
“careful balance between the need to promote innovation” and allowing the
public to use and perfect the invention “for the lifeblood of a competitive
economy”).
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2. Amending 35 U.S.C. § 102136
35 U.S.C. § 102 is the patent law novelty provision. Currently
the invention is anticipated if, it was known, used, patented or
published prior to invention by the applicant.137 To protect known
small molecules with an F.D.A. approved use the following should
be added to the statute:138
A person shall be entitled to a patent unless . . . (h) In regard to
known chemical compounds with a new F.D.A. approved use, the
compound is currently in public use or commercialized.

The limitations included in the § 102 amendment resemble
those suggested in the § 101 amendment. The limitation of “F.D.A.
approved use” again limits the exception to medicinal compounds,
and the limits of “public use” and “commercialized” prevents
removal of currently used chemical compounds from the public.139
B. A Simple Common Law Fix
A simple interpretation of the common law may provide the
protection necessary for known small molecules with a new
medicinal use. Obviousness expanded the novelty requirement by
allowing the combination of elements from multiple disclosures.140
However, a prima facie obviousness analysis will be defeated if a
compound shows unexpected properties.141 Thus, a compound’s

136. The important parts of 35 U.S.C. § 102 for this discussion state:
A
person
shall
be
entitled
to
a
patent
unless—
(a) the invention was known or used by others in this country, or
patented or described in a printed publication in this or a foreign
country, before the invention thereof by the applicant for patent, or
(b) the invention was patented or described in a printed publication
in this or a foreign country or in public use or on sale in this country,
more than one year prior to the date of the application for patent in
the
United
States,
or . . .
(e) the invention was described in (1) an application for patent,
published under section 122(b), by another filed in the United States
before the invention by the applicant for patent or (2) a patent
granted on an application for patent by another filed in the United
States before the invention by the applicant for patent. . . .
35 U.S.C. § 102(a)-(b), (e).
137. Id.
138. See id. (beginning “a person shall be entitled to a patent unless— . . .
.”).
139. See Bilski, 130 S. Ct. at 3252-53 (discussing the balance between
innovation and public use).
140. See Appl. of Winslow, 365 F.2d at 1018-19 (combining multiple
references to find the invention not patentable).
141. See In re Grabiak, 769 F.2d. at 731 (finding no prima facie case because
prior art did not teach similarity between a thioester and an ester group); see

Do Not Delete

2012]

10/27/2012 3:08 PM

Updating the Patent System’s Novelty Requirement

1173

properties are elements.
Recognizing a compound’s properties as elements will deliver
many compounds from anticipation. Under the case law
interpretation of 35 U.S.C § 102 a single disclosure must contain
each and every element of the invention to anticipate another
invention.142 Thus, if properties are determined to be elements, a
compound is only anticipated if the disclosure describes the
chemical structure and the compound’s properties of interest.
At first glance this interpretation seems to cause inherent
conflicts within § 102.143 Under 35 U.S.C. § 102 an invention is
anticipated if, it was known, used, patented, or published prior to
invention by the applicant.144 However, the elemental analysis
proposed easily dodges the known and published prior art because
the properties are not known or described. Of course, the use or
patented limitations require interpretation.
A simple interpretation of “use” and “patented” can protect all
parties, providing incentive to perform drug research and
preventing unnecessary removal of inventions from the public.145
Note, the public cannot use the compound as a medicine without
F.D.A. approval.146 So, without F.D.A. approval the public did not
lose use of a drug. Further, the “use” limitation shall prevent
composition-of-matter protection if the compound is commercially
produced, or publicly used. Likewise, a new compound cannot
supersede current patent claims.147 However, under this
interpretation if the compound is claimed for a new property, and
the compound is not currently commercially produced, a new
inventor may re-patent the compound with full composition-ofmatter protection after the prior patent expires. Thus, this
interpretation provides incentive to scientists to research known
small molecules and promotes small-molecule medicinal progress.
C. A New Medicinal Innovation Act
Congress has used the monopoly power outside of patent law.
Examples include the 180-day exclusivity in the Hatch-Waxman

also Appl. of Wilder, 563 F.2d at 459-60 (finding prima facie case of
obviousness for adjacent homologs and structural isomers); see also In re May,
574 F.2d at 1089-90 (finding a prima facie case of obviousness for
steroisomers); see also In re Hoch, 428 F.2d at 1342 (finding a prima facie case
for acid and ethyl ester).
142. Hoover Grp. Inc., 66 F.3d at 302; Structural Rubber Prod. Co., 749 F.2d
at 716; Scripps Clinic & Research Found., 927 F.2d at 1576.
143. See generally 35 U.S.C. § 102(a)-(c) (2011).
144. Id.
145. See Bilski, 130 S. Ct. at 3252-53 (discussing the balance between
innovation and public use).
146. 21 U.S.C. § 355(a)-(b).
147. 35 U.S.C. § 102(a), (e).
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Act148 and F.D.A. granted exclusivity, such as The Orphan Drug
Act.149
Likewise, Congress may provide incentive to discover medical
properties of known small molecules by enacting a New Medicinal
Innovation Act. The act must posses: (1) a fourteen to seventeen
year composition-of-matter exclusivity term, with the exclusivity
term beginning after F.D.A. approval;150 and (2) complete
composition-of-matter protection if the compound is not produced
commercially or publicly used. The removal of small-molecule
medicines from the current novelty via chemical structure regime
will promote small-molecule medicinal progress.
V. CONCLUSION
In conclusion, the current patent system fails to efficiently
utilize the medicinal chemical space and to promote progress.151
The novelty provision prevents development of compounds known

148. Mehl, supra note 71.
149. See Michael Dunn, Timing of Patent Filing and Market Exclusivity, 10
NATURE REVIEWS DRUG DISC. 487, 487 (2011) (explaining that the F.D.A
“provides 5 years [exclusivity] for a new chemical entity (NCE), 3 years for a
new formulation . . . and 7 years for an orphan drug”); see also Randy Osborne,
Brand Biologics Grab 12 Years’ Exclusivity, for Now, 27 NATURE
BIOTECHNOLOGY 677, 677 (2009) (noting twelve years data exclusivity for
biologic drugs).
“The Orphan Drug Act (ODA) has been recognized as one of the most
successful US legislative actions in recent history.” Marlene E. Haffner et al.,
Two Decades of Orphan Product Development, 1 NATURE REVIEWS DRUG DISC.
821, 821 (2002). Prior to the Act few companies worked on rare diseases
because the small market could not balance the cost of drug development. Id.
The ODA’s purpose is to “stimulate the development of drugs . . . for the
treatment of rare diseases.” Id. The legislation offers drug developers a
number of incentives including seven years of market exclusivity. Cheung et
al., supra note 71, at 185. Unlike the exclusivity provided via patents, the
ODA’s exclusivity does not initiate until the F.D.A. grants approval. Id. In
addition, the F.D.A. may not admit another orphan drug for the rare disease
for the seven-year period. Id. “Orphan exclusivity is often considered to be a
more comprehensive incentive than a patent” because there are not novelty or
obviousness requirements and the exclusivity begins at approval, not
application. Haffner et al., supra, at 822-23. Other countries, including Japan
and the EU, followed suit, passing ODA like legislation. Cheung et al., supra
note 71, at 188.
150. See 35 U.S.C. § 154(a)(2) (granting patent protection for up to twenty
years after filing a patent application); see also 35 U.S.C. § 154(b)(1)(B)
(extending patent life for patent office delays beyond three years, leaving a
seventeen year patent term); see also Dunn, supra note 146, at 488 (indicating
that the Hatch-Waxman Act limits patent term extensions to a maximum of
fourteen years); see also Cheung et al., supra 71, at 185 (noting the exclusivity
of The Orphan Drug Act initiates post F.D.A. approval).
151. See supra § III and corresponding endnotes (showing that the novelty
requirement stifles medicinal progress).
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but never used.152 Simply, prior art via chemical structure instead
of chemical properties is wasteful153 because it pushes research
away from compounds with drug-like properties.154
Three propositions to promote medicinal progress are
included in this Comment. The propositions include: (1) amending
35 U.S.C. § 101 and/or § 102; (2) providing a common law
interpretation where courts must include a compound’s properties
in the invention’s elements when determining anticipation; or (3)
drafting new legislation that provides exclusivity and compositionof-matter protection for new drugs developed from known small
molecules. If adopted, any of these proposals will promote smallmolecule medicinal progress.

152. See supra § III(B)(2) and corresponding endnotes (declaring prior art by
chemical structure leads to inefficient use of chemical space).
153. Id.
154. See supra § III(B)(3) and corresponding endnotes (showing that
medicinal chemical space is finite).
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